{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:25:43Z","timestamp":1790821543276,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.msard.2019.101863","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T02:52:59Z","timestamp":1574304779000},"page":"101863","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0431-7067","authenticated-orcid":false,"given":"John","family":"Foley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Carrillo-Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karleyton","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Ran","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachna","family":"Kasliwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stangel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Vermersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8675-1723","authenticated-orcid":false,"given":"Michael","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Marinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Smirnakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2019.101863_bib0001","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.msard.2015.08.008","article-title":"Natalizumab-induced hepatic injury: a case report and review of literature","volume":"4","author":"Antezana","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2019.101863_bib0002","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1365-2036.2010.04262.x","article-title":"Clinically significant liver injury in patients treated with natalizumab","volume":"31","author":"Bezabeh","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.msard.2019.101863_bib0003","unstructured":"Biogen, 2016. Physician information and management guidelines for multiple sclerosis patients on TYSABRI therapy. <https:\/\/www.hpra.ie\/docs\/default-source\/3rd-party-documents\/tysabri-physician-information-and-management-guidelines-(version-15-27th-april-2016).pdf?sfvrsn=2>(accessed June 28, 2019)."},{"key":"10.1016\/j.msard.2019.101863_bib0004","unstructured":"Biogen, 2019. Medical information website. <https:\/\/medinfo.biogen.com\/medinfo>(accessed August 12, 2019)."},{"key":"10.1016\/j.msard.2019.101863_bib0005","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2019.101863_bib0006","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/jnnp-2013-306936","article-title":"Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results","volume":"85","author":"Butzkueven","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2019.101863_bib0007","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","article-title":"The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL","volume":"69","author":"Calabresi","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.101863_bib0008","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/1352458510388966","article-title":"An approach to natalizumab hypersensitivity: a case series of induction of tolerance","volume":"17","author":"Camacho-Halili","year":"2011","journal-title":"Mult. Scler."},{"issue":"564","key":"10.1016\/j.msard.2019.101863_bib0009","first-page":"P1094","article-title":"No evidence of an increased risk for malignancy associated with natalizumab therapy in 9 years of postmarketing surveillance","volume":"23","author":"Carrillo-Infante","year":"2015","journal-title":"Mult. Scler"},{"key":"10.1016\/j.msard.2019.101863_bib0010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/105294199277860","article-title":"The International Conference on Harmonization good clinical practice guideline","volume":"6","author":"Dixon","year":"1998","journal-title":"Qual. Assur."},{"key":"10.1016\/j.msard.2019.101863_bib0011","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acn3.114","article-title":"Outcome and survival of asymptomatic PML in natalizumab-treated MS patients","volume":"1","author":"Dong-Si","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2019.101863_bib0012","series-title":"GLOBOCAN 2012 v1.0. Cancer Incidence and Mortality Worldwide","author":"Ferlay","year":"2013"},{"key":"10.1016\/j.msard.2019.101863_bib0013","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008933.pub2","article-title":"Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis","author":"Filippini","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.msard.2019.101863_bib0014","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/cid\/cit376","article-title":"Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients","volume":"57","author":"Fine","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.msard.2019.101863_bib0015","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1177\/1352458517702533","article-title":"Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis","volume":"23","author":"Foley","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.101863_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165027","article-title":"Risk of premenopausal and postmenopausal breast cancer among multiple sclerosis patients","volume":"11","author":"Hajiebrahimi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2019.101863_bib0017","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2019.101863_bib0018","unstructured":"Howlader, N., Noone, A., Krapcho, M., et\u00a0al., 2017. SEER cancer statistics review, 1975\u20132014. <https:\/\/seer.cancer.gov\/csr\/1975_2014\/>(accessed July 8, 2019)."},{"key":"10.1016\/j.msard.2019.101863_bib0019","series-title":"European Committee for Treatment & Research in Multiple Sclerosis, Berlin, Germany; October 10\u201312, 2018","article-title":"Real-world data from over 10 years in the TYSABRI\u00ae Observational Program: long-term safety and effectiveness of natalizumab in relapsing-remitting multiple sclerosis patients","author":"Kappos","year":"2018"},{"key":"10.1016\/j.msard.2019.101863_bib0020","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s00415-011-5929-9","article-title":"Cancer and multiple sclerosis in the era of disease-modifying treatments","volume":"258","author":"Lebrun","year":"2011","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2019.101863_bib0021","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis","volume":"348","author":"Miller","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2019.101863_bib0022","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/ijc.21437","article-title":"Cancer risk among patients with multiple sclerosis: a population-based register study","volume":"118","author":"Nielsen","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.msard.2019.101863_bib0023","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2019.101863_bib0024","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2019.101863_bib0025","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/ene.12267","article-title":"Increased breast cancer risk for patients with multiple sclerosis: a nationwide population-based cohort study","volume":"21","author":"Sun","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2019.101863_bib0026","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/cpt.207","article-title":"Drug-induced progressive multifocal leukoencephalopathy: lessons learned from contrasting natalizumab and rituximab","volume":"98","author":"Vermeer","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.msard.2019.101863_bib0027","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.msard.2016.07.012","article-title":"Three cases of herpes zoster radiculitis in MS patients treated with natalizumab","volume":"9","author":"Yamout","year":"2016","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819309356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819309356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:46:32Z","timestamp":1761900392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034819309356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":27,"alternative-id":["S2211034819309356"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.101863","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.101863","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101863"}}